BEAP inhibits the proliferation of lung-cancer-cell-line A549 by inducing apoptosis through increasing the Bax/Bcl-2 ratio, promoting the release of cytochrome C and activating caspase-3 and caspase-9. Here, CASP9 is linked to lung carcinoma.